Zobrazeno 1 - 10 of 10 pro vyhledávání: '"María Jesús Ortiz-Ruiz"'
1
Akademický článek
Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target.
Autor: Juan Carlos Montero, Alberto Ocaña, Mar Abad, María Jesús Ortiz-Ruiz, Atanasio Pandiella, Azucena Esparís-Ogando
Publikováno v: PLoS ONE, Vol 4, Iss 5, p e5565 (2009)
BACKGROUND: Breast cancer is the most common neoplasia in women. Even though advances in its treatment have improved disease outcome, some patients relapse. Therefore, attempts to better define the molecular determinants that drive breast cancer cell
Externí odkaz: https://doaj.org/article/54878656132349f8b6aa66b08c130f59
Zobrazit plný text záznamu
4
Data from Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor
Autor: Atanasio Pandiella, Azucena Esparís-Ogando, Francis J. Burrows, Jesús San Miguel, Enrique M. Ocio, Sara Zaknoen, Tracy Parrott, María Jesús Ortiz-Ruiz, Stela Álvarez-Fernández
Purpose: To analyze the antimyeloma potential of TG02, an ERK5/CDK inhibitory drug.Experimental Design: Utilizing different multiple myeloma cell lines we determined the effect of TG02 over viability by MTT assays. The apoptotic effect over multiple
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::992eac3a070d9fa9c2a0355ce6083f3e
https://doi.org/10.1158/1078-0432.c.6520782
Zobrazit plný text záznamu
5
MEK5 promotes lung adenocarcinoma
Autor: María Florencia Re-Louhau, Adrián Sánchez-Fdez, Dolores Ludeña, Óscar Blanco-Múñez, Azucena Esparís-Ogando, Isabel Ramos, Manuel Sánchez-Martín, María Jesús Ortiz-Ruiz, M. Abad, Atanasio Pandiella
Publikováno v: The European Respiratory Journal
Lung cancer represents the leading cause of cancer death worldwide [1]. Because of that, intense efforts are being devoted to the development of novel therapeutic strategies to fight the disease [2]. In this respect, identification of new oncogenic d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b45cbcbd1087ee4b6df2aa20214e5515
http://europepmc.org/articles/PMC6393765
Zobrazit plný text záznamu
6
Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor
Autor: Enrique M. Ocio, Francis Burrows, María Jesús Ortiz-Ruiz, Sara Zaknoen, Stela Álvarez-Fernández, Tracy Parrott, Atanasio Pandiella, Jesús F. San Miguel, Azucena Esparís-Ogando
Publikováno v: Digital.CSIC. Repositorio Institucional del CSIC
instname
[Purpose]: To analyze the antimyeloma potential of TG02, an ERK5/CDK inhibitory drug. [Experimental Design]: Utilizing different multiple myeloma cell lines we determined the effect of TG02 over viability by MTT assays. The apoptotic effect over mult
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3b05d0e29457f5315e02b860e90d781
https://doi.org/10.1158/1078-0432.ccr-12-2118
Zobrazit plný text záznamu
7
Therapeutic potential of ERK5 targeting in triple negative breast cancer
Autor: Alberto Ocaña, María Jesús Ortiz-Ruiz, Sara Zaknoen, Azucena Esparís-Ogando, Francis Burrows, Atanasio Pandiella, Stela Álvarez-Fernández, Tracy Parrott
Publikováno v: ResearcherID
Oncotarget
Digital.CSIC. Repositorio Institucional del CSIC
instname
Scopus-Elsevier
Europe PubMed Central
Licensed under a Creative Commons Attribution 3.0 License.
Triple negative breast cancers (TNBCs) account for 15% of all breast cancers, and represent one of the most aggressive forms of the disease, exhibiting short relapse-free survival. In co
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b09fe705a382c6e2c6c721c178bc0cc
http://hdl.handle.net/10261/134056
Zobrazit plný text záznamu
8
Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target
Autor: María Jesús Ortiz-Ruiz, Alberto Ocaña, María del Mar Abad, Azucena Esparís-Ogando, Atanasio Pandiella, Juan Carlos Montero
Publikováno v: PLoS ONE
PLoS ONE, Vol 4, Iss 5, p e5565 (2009)
Background Breast cancer is the most common neoplasia in women. Even though advances in its treatment have improved disease outcome, some patients relapse. Therefore, attempts to better define the molecular determinants that drive breast cancer cell
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a4bb28694ed5c7ffc851d027feac03d
http://europepmc.org/articles/PMC2678256
Zobrazit plný text záznamu
9
Abstract A153: Effect of the multikinase inhibitor TG02 in HER2-positive breast cancer
Autor: Azucena Esparís-Ogando, Atanasio Pandiella, Francis Burrows, María Jesús Ortiz-Ruiz
Publikováno v: Molecular Cancer Therapeutics. 10:A153-A153
Breast cancer represents a heterogeneous disease in which several distinct genetic and histopathological types have been defined. Depending on the latter, treatment is established based on the presence of estrogen or progesterone receptors, the trans
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0e53e4bc49bf2d820177a62698963db5
https://doi.org/10.1158/1535-7163.targ-11-a153
Zobrazit plný text záznamu
10
Abstract B268: Tyrosine kinase profiling in head and neck cancer tumors in combination with clinical prognosis factors guides therapeutic combination strategies
Autor: Rafael Lopez‐Castro, Juan Jesús Cruz, María Jesús Ortiz-Ruiz, Atanasio Pandiella, Ruth Rodriguez-Barrueco, Alberto Ocaña
Publikováno v: Molecular Cancer Therapeutics. 8:B268-B268
Background: Tyrosine kinases (TK) are a particular subgroup of proteins implicated in the genesis/progression of Squamous cell carcinoma of the head and neck (SCCHN). Therapeutic inhibition of several of them has shown to be clinically useful, as is
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2a69700433eb9cc785add6da34b2d2e4
https://doi.org/10.1158/1535-7163.targ-09-b268
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje